FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1813126099> ?p ?o ?g. }

• W1813126099 endingPage "589" @default.
• W1813126099 startingPage "579" @default.
• W1813126099 abstract "Summary This Phase II study assessed feasibility and efficacy of a biweekly R‐COMP‐14 regimen (rituximab, cyclophosphamide, non‐pegylated liposome‐encapsulated doxorubicin, vincristine and prednisone) in untreated elderly patients with poor‐risk diffuse large B‐cell lymphoma (DLBCL) and moderate to high ‘life threat’ impact NIA/NCI cardiac comorbidity. A total of 208 courses were delivered, with close cardiac monitoring, to 41 patients (median age: 73 years, range: 62–82; 37% >75 years) at a median interval of 15·6 (range, 13–29) days; 67% completed all six scheduled courses. Response rate was 73%, with 68% complete responses (CR); 4‐year disease‐free survival (DFS) and time to treatment failure (TTF) were 72% and 49%, respectively. Failures were due to early death ( n = 3), therapy discontinuations (no‐response n = 2; toxicity n = 6), relapse ( n = 6) and death in CR ( n = 3). Incidence of cardiac grade 3–5 adverse events was 7/41 (17%; 95% confidence interval: 8–31%). Time to progression and overall survival at 4‐years were 77% and 67%, respectively. The Age‐adjusted Charlson Comorbidity Index (aaCCI) correlated with failures ( P = 0·007) with patients scoring ≤7 having a longer TTF (66% vs. 29%; P = 0·009). R‐COMP‐14 is feasible and ensures a substantial DFS to poor‐risk DLBCL patients who would have been denied anthracycline‐based treatment due to cardiac morbidity. The aaCCI predicted both treatment discontinuation rate and TTF." @default.
• W1813126099 created "2016-06-24" @default.
• W1813126099 creator A5008520736 @default.
• W1813126099 creator A5009029772 @default.
• W1813126099 creator A5016024062 @default.
• W1813126099 creator A5023238523 @default.
• W1813126099 creator A5024386803 @default.
• W1813126099 creator A5033029228 @default.
• W1813126099 creator A5035514953 @default.
• W1813126099 creator A5040824984 @default.
• W1813126099 creator A5041446245 @default.
• W1813126099 creator A5054592096 @default.
• W1813126099 creator A5056367154 @default.
• W1813126099 creator A5059776581 @default.
• W1813126099 creator A5063945951 @default.
• W1813126099 creator A5073061488 @default.
• W1813126099 creator A5077919557 @default.
• W1813126099 creator A5087147482 @default.
• W1813126099 date "2011-06-28" @default.
• W1813126099 modified "2023-10-17" @default.
• W1813126099 title "Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy" @default.
• W1813126099 cites W1510894885 @default.
• W1813126099 cites W1892459592 @default.
• W1813126099 cites W1911376378 @default.
• W1813126099 cites W1975131435 @default.
• W1813126099 cites W1978339493 @default.
• W1813126099 cites W1980032822 @default.
• W1813126099 cites W1983644735 @default.
• W1813126099 cites W2000445173 @default.
• W1813126099 cites W2004588047 @default.
• W1813126099 cites W2006350183 @default.
• W1813126099 cites W2022760931 @default.
• W1813126099 cites W2024075791 @default.
• W1813126099 cites W2030472249 @default.
• W1813126099 cites W2038023916 @default.
• W1813126099 cites W2041330854 @default.
• W1813126099 cites W2042155497 @default.
• W1813126099 cites W2055044789 @default.
• W1813126099 cites W2065749162 @default.
• W1813126099 cites W2067139305 @default.
• W1813126099 cites W2067664068 @default.
• W1813126099 cites W2072430038 @default.
• W1813126099 cites W2078237412 @default.
• W1813126099 cites W2078729915 @default.
• W1813126099 cites W2080217593 @default.
• W1813126099 cites W2090827677 @default.
• W1813126099 cites W2090977926 @default.
• W1813126099 cites W2095308469 @default.
• W1813126099 cites W2103737663 @default.
• W1813126099 cites W2106101265 @default.
• W1813126099 cites W2106810047 @default.
• W1813126099 cites W2106928992 @default.
• W1813126099 cites W2108465006 @default.
• W1813126099 cites W2109775164 @default.
• W1813126099 cites W2117647659 @default.
• W1813126099 cites W2122265695 @default.
• W1813126099 cites W2127785542 @default.
• W1813126099 cites W2130860651 @default.
• W1813126099 cites W2133201432 @default.
• W1813126099 cites W2133528707 @default.
• W1813126099 cites W2139059338 @default.
• W1813126099 cites W2142660045 @default.
• W1813126099 cites W2144495510 @default.
• W1813126099 cites W2145770938 @default.
• W1813126099 cites W2152124377 @default.
• W1813126099 cites W2166342496 @default.
• W1813126099 cites W2167571754 @default.
• W1813126099 cites W2229459582 @default.
• W1813126099 cites W2462063282 @default.
• W1813126099 cites W2760092279 @default.
• W1813126099 cites W2909539111 @default.
• W1813126099 cites W4205736005 @default.
• W1813126099 cites W4366064733 @default.
• W1813126099 doi "https://doi.org/10.1111/j.1365-2141.2011.08786.x" @default.
• W1813126099 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3258483" @default.
• W1813126099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21707585" @default.
• W1813126099 hasPublicationYear "2011" @default.
• W1813126099 type Work @default.
• W1813126099 sameAs 1813126099 @default.
• W1813126099 citedByCount "49" @default.
• W1813126099 countsByYear W18131260992012 @default.
• W1813126099 countsByYear W18131260992013 @default.
• W1813126099 countsByYear W18131260992014 @default.
• W1813126099 countsByYear W18131260992015 @default.
• W1813126099 countsByYear W18131260992016 @default.
• W1813126099 countsByYear W18131260992017 @default.
• W1813126099 countsByYear W18131260992018 @default.
• W1813126099 countsByYear W18131260992019 @default.
• W1813126099 countsByYear W18131260992020 @default.
• W1813126099 countsByYear W18131260992021 @default.
• W1813126099 countsByYear W18131260992022 @default.
• W1813126099 countsByYear W18131260992023 @default.
• W1813126099 crossrefType "journal-article" @default.
• W1813126099 hasAuthorship W1813126099A5008520736 @default.
• W1813126099 hasAuthorship W1813126099A5009029772 @default.
• W1813126099 hasAuthorship W1813126099A5016024062 @default.
• W1813126099 hasAuthorship W1813126099A5023238523 @default.
• W1813126099 hasAuthorship W1813126099A5024386803 @default.

• next